-
The Growing Landscape of FDA-Approved Peptide Therapies for Weight Management
Peptide-based medications continue to expand as a legitimate, FDA-regulated option for weight management, reflecting growing scientific and regulatory confidence in this class of treatments.
-
FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management
The FDA has approved several peptide-based medications for weight management, reflecting growing confidence in this class of therapies as a tool to support healthier body weight.
-
New Phase 3 Trial Launches to Explore Rina-S for Ovarian Cancer Maintenance Therapy
A global Phase 3 study is now underway to evaluate whether Rina-S, used alone or alongside standard care, can improve outcomes for ovarian cancer patients following first-line chemotherapy. The trial will enroll up to 602 participants across multiple countries.
-
New Phase II Trial Explores Triple Combination Therapy for Richter Transformation
Researchers are launching a phase II trial combining acalabrutinib, venetoclax, and durvalumab to treat Richter transformation, a rare and aggressive complication of chronic lymphocytic leukemia.
-
New Clinical Trial Explores RYZ101 as Next-Step Therapy for Advanced Neuroendocrine Tumors
A Phase 3 study is evaluating RYZ101, a targeted radiopharmaceutical peptide, as a potential treatment option for patients with advanced GEP-NETs that have progressed after standard 177Lu-SSA therapy. The trial offers hope for patients who currently have limited options.
-
FDA Unveils Faster 50-Day Review Pathway for Novel Drugs, Including Peptide Therapeutics
The FDA has introduced a streamlined 50-day review option for new molecular entities, a change that could accelerate the path to approval for innovative peptide-based medicines.
-
FDA Advisory Panel Recommends Expanded Access to Six Popular Peptides
An FDA advisory panel has voiced support for expanding access to six peptides, a move that could make these compounds more readily available through compounding pharmacies.
-
FDA Green-Lights Peptide-Based Treatments for Weight Loss
The FDA has approved peptide-based drugs for weight management, expanding access to a new class of treatments for individuals seeking medically supervised support for weight loss.
-
Health Canada Approves Generic Semaglutide, Paving Way for Broader Access
Apotex has received Health Canada approval for a generic version of semaglutide, a milestone that could eventually improve affordability and availability of this widely used peptide therapy for Canadian patients.
-
Peptide-Based Weight Loss Treatments Continue to Gain FDA Recognition
The FDA’s continued approval and expansion of peptide-based weight loss medications highlights growing confidence in this class of treatments for obesity and metabolic health.